Cromwell Holdings LLC Decreases Holdings in Thermo Fisher Scientific Inc. $TMO

Cromwell Holdings LLC trimmed its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 79.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 223 shares of the medical research company’s stock after selling 877 shares during the period. Cromwell Holdings LLC’s holdings in Thermo Fisher Scientific were worth $91,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Hilltop National Bank purchased a new stake in Thermo Fisher Scientific during the 2nd quarter worth $339,000. Mechanics Financial Corp boosted its position in Thermo Fisher Scientific by 53.9% during the 2nd quarter. Mechanics Financial Corp now owns 3,148 shares of the medical research company’s stock worth $1,276,000 after purchasing an additional 1,102 shares during the period. Syntax Research Inc. boosted its position in Thermo Fisher Scientific by 6,389.8% during the 2nd quarter. Syntax Research Inc. now owns 5,711 shares of the medical research company’s stock worth $2,316,000 after purchasing an additional 5,623 shares during the period. Patriot Financial Group Insurance Agency LLC purchased a new stake in Thermo Fisher Scientific during the 2nd quarter worth $220,000. Finally, Kennebec Savings Bank boosted its position in Thermo Fisher Scientific by 8.9% during the 2nd quarter. Kennebec Savings Bank now owns 1,478 shares of the medical research company’s stock worth $599,000 after purchasing an additional 121 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

TMO has been the subject of a number of analyst reports. Wells Fargo & Company decreased their price objective on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an “overweight” rating for the company in a research report on Thursday, July 24th. William Blair initiated coverage on shares of Thermo Fisher Scientific in a research report on Monday, August 18th. They issued an “outperform” rating for the company. Hsbc Global Res cut shares of Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 24th. Robert W. Baird upped their price objective on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an “outperform” rating in a research report on Thursday, July 24th. Finally, HSBC reissued a “hold” rating and issued a $510.00 price objective on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Fifteen analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $585.37.

Insider Buying and Selling

In related news, CEO Marc N. Casper sold 400 shares of the stock in a transaction dated Friday, September 5th. The shares were sold at an average price of $500.50, for a total transaction of $200,200.00. Following the sale, the chief executive officer owned 113,762 shares in the company, valued at $56,937,881. This represents a 0.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 30,066 shares of company stock worth $14,182,963 over the last quarter. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock opened at $525.07 on Friday. The firm has a market cap of $198.27 billion, a PE ratio of 30.37, a price-to-earnings-growth ratio of 2.88 and a beta of 0.77. The firm’s 50-day simple moving average is $481.27 and its 200-day simple moving average is $447.60. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $611.49.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.22 by $0.14. The business had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company’s revenue for the quarter was up 2.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be paid a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is 9.95%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.